lncRNA ZEB1-AS1 inhibits high glucose-induced EMT and fibrogenesis by regulating the miR-216a-5p/BMP7 axis in diabetic nephropathy

Meng, Qingqing; Zhai, Xiaolin; Yuan, Yixuan; Ji, Qing; Zhang, Pengyuan

doi:10.1590/1414-431x20209288

Cited by 25 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When expressed, this gene acts as an oncogenic regulator in many human tumors (Ni et al, 2020). Meng and Zhai (2020) demonstrated that ZEB1-AS1 overexpression inhibits HG-induced RF by suppressing EMT and fibrogenesis. Mechanistically, they identified that ZEB1-AS1 impedes RF by regulating BMP7 expression and inhibits EMT of HK-2 cells by competitively binding to miR-216a-5p (Meng and Zhai, 2020).…”

Section: Lncrna Zeb1-as1mentioning

confidence: 99%

Long Non-coding RNA: An Emerging Contributor and Potential Therapeutic Target in Renal Fibrosis

Xia

Gan

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

Renal fibrosis (RF) is a pathological process that culminates in terminal renal failure in chronic kidney disease (CKD). Fibrosis contributes to progressive and irreversible decline in renal function. However, the molecular mechanisms involved in RF are complex and remain poorly understood. Long non-coding RNAs (lncRNAs) are a major type of non-coding RNAs, which significantly affect various disease processes, cellular homeostasis, and development through multiple mechanisms. Recent investigations have implicated aberrantly expressed lncRNA in RF development and progression, suggesting that lncRNAs play a crucial role in determining the clinical manifestation of RF. In this review, we comprehensively evaluated the recently published articles on lncRNAs in RF, discussed the potential application of lncRNAs as diagnostic and/or prognostic biomarkers, proposed therapeutic targets for treating RF-associated diseases and subsequent CKD transition, and highlight future research directions in the context of the role of lncRNAs in the development and treatment of RF.

show abstract

Section: Lncrna Zeb1-as1mentioning

confidence: 99%

Long Non-coding RNA: An Emerging Contributor and Potential Therapeutic Target in Renal Fibrosis

Xia

Gan

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…LncRNA zinc finger E-box binding homeobox 1 antisense 1 (ZEB1-AS1) plays a protective role in DKD by targeting profibrotic miR-216a-5p to inhibit HK-induced EMT and renal fibrosis. Besides, the anti-fibrotic function of ZEB1-AS1 is also verified that it may bind to H3K4 methyltransferase myeloid and lymphoid or mixed-lineage leukemia 1 (MLL1) and p53 in patients with DKD ( Wang et al, 2018a ; Meng et al, 2020 ). lncRNA NR_038323 exerts an anti-fibrotic effect by interacting with miR-324-3p.…”

Section: The Emerging Role Of Non-coding Rnas In Dkdmentioning

confidence: 87%

Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease

Huang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is the most common diabetic complication and is a leading cause of end-stage kidney disease. Increasing evidence shows that DKD is regulated not only by many classical signaling pathways but also by epigenetic mechanisms involving chromatin histone modifications, DNA methylation, and non-coding RNA (ncRNAs). In this review, we focus on our current understanding of the role and mechanisms of ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) in the pathogenesis of DKD. Of them, the regulatory role of TGF-β/Smad3-dependent miRNAs and lncRNAs in DKD is highlighted. Importantly, miRNAs and lncRNAs as biomarkers and therapeutic targets for DKD are also described, and the perspective of ncRNAs as a novel therapeutic approach for combating diabetic nephropathy is also discussed.

show abstract

“…NRP-1 undergoes upregulation in PCa cells, resulting in proliferation and malignancy ( Figure 11 ) [ 216 , 217 ]. Additionally, zinc finger E-box binding homeobox 1 (ZEB1) is an upstream mediator of EMT and contributes to the metastasis and invasion of cancer cells via the induction of EMT [ 218 , 219 ]. Accumulating data demonstrate that ZEB1 has high expression in PCa cancer cells and is correlated with the progression and metastasis of these cancer cells [ 220 , 221 ].…”

Section: Nano-vehiclesmentioning

confidence: 99%

Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer

et al. 2020

View full text Add to dashboard Cite

Prostate cancer (PCa) accounts for a high number of deaths in males with no available curative treatments. Patients with PCa are commonly diagnosed in advanced stages due to the lack of symptoms in the early stages. Recently, the research focus was directed toward gene editing in cancer therapy. Small interfering RNA (siRNA) intervention is considered as a powerful tool for gene silencing (knockdown), enabling the suppression of oncogene factors in cancer. This strategy is applied to the treatment of various cancers including PCa. The siRNA can inhibit proliferation and invasion of PCa cells and is able to promote the anti-tumor activity of chemotherapeutic agents. However, the off-target effects of siRNA therapy remarkably reduce its efficacy in PCa therapy. To date, various carriers were designed to improve the delivery of siRNA and, among them, nanoparticles are of importance. Nanoparticles enable the targeted delivery of siRNAs and enhance their potential in the downregulation of target genes of interest. Additionally, nanoparticles can provide a platform for the co-delivery of siRNAs and anti-tumor drugs, resulting in decreased growth and migration of PCa cells. The efficacy, specificity, and delivery of siRNAs are comprehensively discussed in this review to direct further studies toward using siRNAs and their nanoscale-delivery systems in PCa therapy and perhaps other cancer types.

show abstract

lncRNA ZEB1-AS1 inhibits high glucose-induced EMT and fibrogenesis by regulating the miR-216a-5p/BMP7 axis in diabetic nephropathy

Cited by 25 publications

References 33 publications

Long Non-coding RNA: An Emerging Contributor and Potential Therapeutic Target in Renal Fibrosis

Long Non-coding RNA: An Emerging Contributor and Potential Therapeutic Target in Renal Fibrosis

Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease

Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer

Contact Info

Product

Resources

About